After 72 weeks, participants on Zepbound lost an average of 20.2% of their body weight (averaging 50 pounds), compared to 13.7% (around 33 pounds) for those on the 2.4 mg dose of Wegovy (later studies of the 7.2 mg dose of Wegovy have showed 18.7% weight loss)
These symptoms are often temporary and improve as the body adjusts.* Medical Monitoring Recommended: Regular follow-up with your healthcare provider is important to monitor progress, evaluate tolerance, and optimize your wellness plan while using GLP-1/GIP therapy.* Not Appropriate for Everyone: GLP-1/GIP therapy may not be suitable for individuals with certain medical conditions including a history of medullary thyroid carcinoma, MEN2 syndrome, pancreatitis, or severe gastrointestinal disorders
Second, sublingual bioavailability varies between doses for the same individual
Rotate injection sites consistently
Try to aim for at least 8 glasses of water per day, especially before and after meals
Gradual yellowing can occur with suboptimal storage conditions and indicates degradation